Dermot Kenny, who leads STEM and Research Partnership at Inizio Advisory, shares his journey from bench scientist to CEO in a new 12 Questions With.
J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
Editor's Picks
